🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
16.69
+0.07 (0.42%)
Nov 20, 2026, 10:01 AM EST - Market open

Xeris Biopharma Holdings Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
368.26291.85203.07163.91110.2549.59
Revenue Growth
38.37%43.72%23.89%48.68%122.32%142.67%
Cost of Revenue
46.4642.5736.8328.6522.6313.32
Gross Profit
321.8249.28166.24135.2787.6136.27
Selling, General & Admin
225.79182.37163.48146.1137.75116.06
Research & Development
38.3831.1725.5622.3420.9725.16
Amortization of Goodwill & Intangibles
10.8410.8410.8410.8410.840.55
Operating Expenses
275.02224.38199.88179.28169.55141.77
Operating Income
46.7824.9-33.65-44.01-81.94-105.5
Interest Expense
-27.44-29.08-30.49-26.61-14.1-7.18
Interest & Investment Income
4.954.745.324.752.580.73
Other Non Operating Income (Expenses)
--0.0101.76-0.7
EBT Excluding Unusual Items
24.290.55-58.8-65.87-91.7-112.66
Merger & Restructuring Charges
------9.66
Gain (Loss) on Sale of Investments
------0.41
Other Unusual Items
-30.78-1.72.36-4.38-
Pretax Income
-6.50.55-57.1-63.5-96.08-122.73
Income Tax Expense
---2.27-1.25-1.42-
Net Income
-6.50.55-54.84-62.26-94.66-122.73
Net Income to Common
-6.50.55-54.84-62.26-94.66-122.73
Net Income Growth
------
Shares Outstanding (Basic)
17316014713813679
Shares Outstanding (Diluted)
17317314713813679
Shares Change
10.49%17.69%6.61%1.51%71.62%85.32%
EPS (Basic)
-0.040.00-0.37-0.45-0.70-1.55
EPS (Diluted)
-0.040.00-0.37-0.45-0.70-1.55
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
72.6227.93-37.85-49.29-103.42-96.62
Free Cash Flow Per Share
0.420.16-0.26-0.36-0.76-1.22
Gross Margin
87.38%85.41%81.86%82.52%79.47%73.14%
Operating Margin
12.70%8.53%-16.57%-26.85%-74.32%-212.74%
Profit Margin
-1.76%0.19%-27.00%-37.98%-85.86%-247.48%
Free Cash Flow Margin
19.72%9.57%-18.64%-30.07%-93.80%-194.84%
EBITDA
58.9437.05-21.58-31.68-69.7-103.62
EBITDA Margin
16.00%12.70%-10.63%-19.33%-63.22%-208.95%
D&A For EBITDA
12.1612.1612.0712.3312.241.88
EBIT
46.7824.9-33.65-44.01-81.94-105.5
EBIT Margin
12.70%8.53%-16.57%-26.85%-74.32%-212.74%
Revenue as Reported
368.26291.85203.07163.91110.2549.59
SEC Filings: 10-K · 10-Q